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AbsTrACT
Objectives to evaluate the diagnostic and prognostic 
benefits of ct coronary angiography (ctca) using the 
2016 national institute for health and care excellence 
(nice) guidelines for the assessment of suspected stable 
angina.
Methods Post hoc analysis of the scottish cOmputed 
tomography of the heart (scOt-heart) trial of 4146 
participants with suspected angina randomised to ctca. 
Patients were dichotomised into nice guideline-defined 
possible angina and non-anginal presentations. Primary 
(diagnostic) endpoint was diagnostic certainty of angina 
at 6 weeks and prognostic endpoint comprised fatal and 
non-fatal myocardial infarction (Mi).
results in 3770 eligible participants, ctca increased 
diagnostic certainty more in those with possible angina 
(relative risk (rr) 2.22 (95% ci 1.91 to 2.60), p<0.001) 
than those with non-anginal symptoms (rr 1.30 (1.11 
to 1.53), p=0.002; pinteraction <0.001). in the possible 
angina cohort, ctca did not change rates of invasive 
angiography (p=0.481) but markedly reduced rates 
of normal coronary angiography (hr 0.32 (0.19 to 
0.52), p<0.001). in the non-anginal cohort, rates of 
invasive angiography increased (hr 1.82 (1.13 to 2.92), 
p=0.014) without reducing rates of normal coronary 
angiography (hr 0.78 (0.30 to 2.05), p=0.622). at 3.2 
years of follow-up, fatal or non-fatal Mi was reduced in 
patients with possible angina (3.2% to 1.9%%; hr 0.58 
(0.34 to 0.99), p=0.045) but not in those with non-
anginal symptoms (hr 0.65 (0.25 to 1.69), p=0.379).
Conclusions nice-guided patient selection maximises 
the benefits of ctca on diagnostic certainty, use of 
invasive coronary angiography and reductions in fatal 
and non-fatal myocardial infarction. Patients with non-
anginal chest pain derive minimal benefit from ctca and 
increase the rates of invasive investigation.
Trial registration number  clinicaltrials. gov: 
nct01149590;post results.
InTrOduCTIOn
Chest pain is a common symptom within the 
community and is responsible for at least 1% of 
all presentations to general practitioners.1 2 It is 
frequently a cause of concern for patients and 
clinicians alike, with both eager to identify or 
exclude potentially serious underlying conditions. 
Although stable coronary heart disease (CHD) is 
responsible for only 10% of such presentations,3 
the resources required to exclude this diagnosis 
have important public health implications. Clearly, 
it is in the interests of all parties to develop an effi-
cient and effective strategy for the assessment and 
management of these symptoms.
In response to this clinical need, the National 
Institute of Health and Care Excellence (NICE) first 
published an innovative guideline (CG95) on the 
assessment of chest pain of recent onset in 2010.4 
This publication encouraged a systematic approach 
to determining the pre-test probability of CHD 
using routinely available clinical features. Further-
more, it established explicit thresholds of risk, below 
which additional investigation for coronary disease 
was regarded as unnecessary and unhelpful. These 
changes were met with initial scepticism related 
to the potential for increased costs,5 underestima-
tion of disease prevalence6 and frequent pathway 
non-adherence arising from the unacceptability of 
discharging low risk patients without further inves-
tigation.7 Fortunately, the ensuing years have allayed 
many of these concerns with more recent studies 
demonstrating an association between increasing 
guideline compliance, reduced diagnostic testing 
and lower overall expenditure.8–10
In November 2016, the NICE guideline was 
updated with two important changes made to 
the recommendations.11 First, the abolition of 
the explicit approach to the estimation of pretest 
probability with patients now selected for further 
testing based simply on the description of chest 
pain or the presence of an abnormal resting ECG. 
Second, driven by technological developments and 
cost reductions, non-invasive testing for myocardial 
ischaemia has been replaced with broad indications 
for CT coronary angiography (CTCA). However, 
concerns have already been raised that this new 
strategy has not been adequately assessed and 
should be tested in a clinical trial.12 We therefore 
aimed to determine the diagnostic and prognostic 
implications of these changes to the assessment of 
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patients presenting with stable chest pain of recent onset using 
the Scottish COmputed Tomography of the HEART (SCOT-
HEART) trial dataset.
MeThOds
study design and population
The SCOT-HEART study is a prospective, multicentre, 
randomised controlled trial investigating the role of CTCA in 
patients referred to a specialist clinic with suspected angina due 
to CHD. The study design13 and principal findings14 have previ-
ously been reported. The study population comprised individ-
uals without a documented history of prior CHD referred for 
assessment of suspected stable angina of recent onset who were 
randomised 1:1 to CTCA plus standard care or standard care 
alone (see online supplementary material). Chest pain symptoms 
were defined as typical angina, atypical angina or non-anginal 
according to established criteria (see online supplementary table 
1).11 An abnormal resting ECG was determined by the pres-
ence of any of the following: pathological Q waves, left bundle 
branch block or either ST segment or T wave abnormalities. As 
per the 2016 NICE guideline recommendations, participants 
were categorised into two groups: those with non-anginal chest 
pain and a normal ECG (non-anginal cohort) and those with 
either typical or atypical chest pain, or non-anginal chest pain 
and an abnormal ECG (possible angina cohort).
Outcomes
The primary (diagnostic) endpoint was clinician certainty (yes/
no vs unlikely/probable) in the diagnosis of angina secondary 
to CHD at 6 weeks. The prognostic endpoint for this study 
was a composite of fatal and non-fatal myocardial infarction. 
Additional secondary endpoints included the requirement for 
invasive coronary angiography, changes in clinician prescribing 
of cardiovascular pharmacotherapy, coronary revascularisation, 
all-cause death and non-fatal stroke.
Outcome data were updated on 29 June 2016 and were 
identified via record linkage from regional and national regis-
tries provided by the Information and Statistics Division of the 
National Health Service (NHS) Scotland and when appropriate, 
confirmed by review of patient health records. Within Scotland, 
this has previously been demonstrated as a robust approach to 
clinical trial endpoint identification.15 Categorisation for anal-
ysis was performed while masked to randomised allocation.
statistical analysis
Statistical analysis was performed using R V.3.3.0 (R Foundation 
for Statistical Computing, Vienna, Austria). All analyses were 
post hoc and were performed stratified by study cohort and 
according to intention-to-treat, irrespective of compliance with 
scanning. Diagnostic endpoints were analysed using log-bino-
mial regression16 17 or log-Poisson regression employing robust 
variance estimates for analysis of those secondary endpoints 
where log-binomial regression failed to converge.18 For ease of 
interpretability, results are reported as the relative risk (RR) with 
95% CIs and p value.19 20 The diagnosis of CHD and angina due 
to CHD (diagnostic endpoints) was assessed for certainty (yes/
no vs unlikely/probable) and change within these four categories. 
Clinical outcome endpoints were analysed with Cox regression 
and reported as HR with cumulative incidence plots constructed. 
In addition to these stratum specific analyses, we modelled inter-
action terms for allocation and study cohort to provide hypoth-
esis testing for interaction on the relative scale. All primary and 
secondary endpoints are reported after adjustment for the mini-
misation variables of age, sex, body mass index, diabetes mellitus 
and atrial fibrillation. Data are presented as mean ± SD or mean 
differences with 95% CIs. Statistical significance was taken as 
two-sided p<0.05.
resulTs
data collection and study population
The study population of the SCOT-HEART trial has previously 
been described.14 Between 18 November 2010 and 24 September 
2014, 4146 participants were recruited of whom four patients had 
incomplete description of their chest pain symptoms recorded and 
were excluded from the analysis. As recommended in the updated 
NICE guidelines, a further 372 participants were excluded from 
the primary analysis due to a documented history of prior CHD. 
The median duration of follow-up was 3.2 years (IQR 2.5 to 4.1). 
In total 1884 were randomly assigned to standard care and 1886 to 
standard care plus CTCA. Of these, three participants allocated to 
standard care and 1616 within the standard care plus CTCA arms 
underwent CTCA at one of three sites (figure 1).
The mean age of the participants was 56.6±9.7 years and 1721 
(45.6%) were women. Overall, 1447 (38.3%) of participants had 
non-anginal symptoms and a normal ECG while 2323 (61.6%) 
participants had symptoms or ECG changes consistent with 
possible angina. The non-anginal cohort were typically younger 
and had fewer cardiovascular risk factors than those with possible 
angina (table 1).
CT coronary angiography
Compared with the non-anginal cohort, participants with possible 
angina were more likely to have obstructive coronary disease iden-
tified on CTCA (29.7% vs9.5%; RR 2.81, 95% CI 2.15 to 3.68, 
Figure 1 Consort diagram. CTCA, CT coronary angiography.
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p<0.001) and less likely to have normal coronary arteries (33.1% 
vs 50.1%; RR 0.74, 95% CI 0.66 to 0.83, p<0.001) (table 2). The 
pretest probability assessment recommended in the 2010 NICE 
guidelines substantially overestimated the risk of obstructive coro-
nary disease (see online supplementary table 3), while the revised 
diagnostic cohorts demonstrated persistent heterogeneity in risk by 
age and sex (see online supplementary table 3). The average rate 
of the primary diagnostic and prognostic endpoints for both men 
and women is presented in online supplementary table 4, and addi-
tional, non-coronary findings made on CTCA are reported in online 
supplementary table 5.
diagnostic certainty and additional investigations
The use of CTCA increased the certainty with which a diagnosis 
of angina was made (figure 2a). This benefit was greatest (cohort 
interaction: p<0.001) in those with possible angina where the 
proportion of participants with a certain diagnosis of angina at 
6 weeks was 34.9% with CTCA and 15.7% with standard care 
(RR 2.22, 95% CI 1.91 to 2.60, p<0.001). The improvement 
in diagnostic certainty remained, although attenuated, in the 
non-anginal cohort (CTCA 32%, standard care 25.2%; RR 1.30, 
95% CI 1.11 to 1.53, p=0.002). The use of CTCA was associ-
ated with a change in diagnosis in 341 (29.0%) participants with 
possible angina and 120 (16.9%) participants with non-anginal 
symptoms. These improvements were associated with treatment 
changes in 26.8% of those with possible angina and 19.4% in 
those with non-anginal chest pain.
The use of CTCA was associated with an increase in new 
requests for invasive coronary angiography at 6 weeks in both 
the possible angina (71 (6.0%) vs 7 (0.6%)) and the non-anginal 
Table 1 Baseline characteristics
All participants non-anginal Possible angina
standard care CT intervention standard care CT intervention
n 3770 735 712 1149 1174
Age (years) 56.62 (9.73) 53.47 (9.68) 54.37 (9.67) 58.52 (9.24) 58.10 (9.50)
Male 2049 (54.4) 405 (55.1) 373 (52.4) 619 (53.9) 652 (55.5)
BMI (kg/m2) 29.69 (5.97) 29.45 (6.38) 29.60 (6.28) 29.88 (5.87) 29.71 (5.60)
Hypertension 1211 (32.1) 172 (23.4) 190 (26.7) 412 (35.9) 437 (37.2)
Hypercholesterolaemia 2078 (55.1) 275 (37.4) 305 (42.8) 742 (64.6) 756 (64.4)
Diabetes mellitus 370 (9.8) 52 (7.1) 63 (8.8) 132 (11.5) 123 (10.5)
Smoking habit
  Never smoked 1816 (48.2) 361 (49.1) 350 (49.2) 548 (47.7) 557 (47.4)
  Ex-smoker 1182 (31.4) 198 (26.9) 203 (28.5) 388 (33.8) 393 (33.5)
  Current smoker 772 (20.5) 176 (23.9) 159 (22.3) 213 (18.5) 224 (19.1)
Atrial fibrillation 76 (2.0) 11 (1.5) 13 (1.8) 25 (2.2) 27 (2.3)
Previous CVD 123 (3.3) 12 (1.6) 25 (3.5) 30 (2.6) 56 (4.8)
Previous PVD 42 (1.1) 3 (0.4) 12 (1.7) 10 (0.9) 17 (1.4)
Family history 1558 (41.3) 285 (38.8) 295 (41.4) 460 (40.0) 518 (44.1)
Antiplatelet agent 1662 (44.1) 126 (17.1) 133 (18.7) 695 (60.5) 708 (60.3)
Statin 1459 (38.7) 121 (16.5) 132 (18.5) 602 (52.4) 604 (51.4)
Beta-blockade 786 (20.8) 46 (6.3) 65 (9.1) 330 (28.7) 345 (29.4)
ACE inhibitor or ARB 497 (13.2) 69 (9.4) 67 (9.4) 171 (14.9) 190 (16.2)
Chest pain symptoms
  Non-anginal 1616 (42.9) 735 (100.0) 712 (100.0) 86 (7.5) 83 (7.1)
  Atypical angina 893 (23.7) 0 (0.0) 0 (0.0) 436 (37.9) 457 (38.9)
  Typical angina 1261 (33.4) 0 (0.0) 0 (0.0) 627 (54.6) 634 (54.0)
Abnormal resting ECG 512 (13.6) 0 (0.0) 0 (0.0) 265 (23.1) 247 (21.0)
Exercise ECG
  Not performed/no result available 758 (20.1) 137 (18.6) 128 (18.0) 249 (21.7) 244 (20.8)
  Normal 2047 (54.3) 544 (74.0) 529 (74.3) 474 (41.3) 500 (42.6)
  Inconclusive 505 (13.4) 40 (5.4) 47 (6.6) 210 (18.3) 208 (17.7)
  Abnormal 460 (12.2) 14 (1.9) 8 (1.1) 216 (18.8) 222 (18.9)
Baseline diagnosis of CHD 1619 (42.9) 69 (9.4) 82 (11.5) 723 (62.9) 745 (63.5)
Baseline diagnosis of angina 1246 (33.1) 9 (1.2) 8 (1.1) 609 (53.0) 620 (52.8)
Predicted 10-year CHD risk* 17.08 (11.57) 13.60 (10.11) 14.99 (10.37) 18.70 (12.35) 18.93 (11.65)
Estimated PTP of CHD (NICE 2010)
  <10% 412 (10.9) 173 (23.5) 163 (22.9) 38 (3.3) 38 (3.2)
  10%–29% 717 (19.0) 255 (34.7) 258 (36.2) 102 (8.9) 102 (8.7)
  30%–59% 997 (26.4) 232 (31.6) 214 (30.1) 266 (23.2) 285 (24.3)
  60%–89% 942 (25.0) 75 (10.2) 77 (10.8) 400 (34.8) 390 (33.2)
  >90% 702 (18.6) 0 (0.0) 0 (0.0) 343 (29.9) 359 (30.6)
*ASSIGN Score (see http://assign-score.com/).
Data are mean (SD) or value (%).
ARB, angiotensin receptor blocker; BMI, body mass index; CHD, coronary heart disease;  CVD, cerebrovascular disease; NICE, National Institute of Health and Care Excellence; PTP, 
pretest probability; PVD, peripheral vascular disease.
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(12 (1.7%) vs 0 (0.0%)) groups. Overall, CTCA only increased 
the total number of angiograms performed during the complete 
follow-up period in the non-anginal cohort (6.6% vs 3.7%; HR 
1.82, 95% CI 1.13 to 2.92, p=0.014), with no change in the 
possible angina cohort (30.2% vs 32.1%; HR 0.95, 95% CI 
0.82 to 1.10, p=0.481) (figure 2a). In participants with possible 
angina, CTCA was associated with a reduced likelihood of the 
invasive angiogram revealing normal coronary arteries (RR 0.32; 
95% CI 0.19 to 0.52, p<0.001) and an increased likelihood of 
identifying obstructive disease (RR 1.18; 95% CI 1.07 to 1.32, 
p=0.002). In contrast, invasive angiography performed in the 
non-anginal cohort demonstrated similar rates of normal arteries 
(RR 0.78; 95% CI 0.30 to 2.05, p=0.622) and obstructive coro-
nary disease (RR 0.82; 95% CI 0.50 to 1.34, p=0.422) in both 
treatment arms (figure 2b).
Clinical outcomes
During follow-up, 18 (1.2%) and 59 (2.5%) of participants 
experienced a fatal or non-fatal myocardial infarction in the 
non-anginal and possible angina groups, respectively (table 3). 
Allocation to standard care with CTCA reduced the likelihood 
of this endpoint in the cohort with possible angina from 3.2% 
to 1.9% (HR 0.58; 95% CI 0.34 to 0.99; p=0.045, figure 3a). 
This was predominantly related to a reduction in non-fatal 
myocardial infarction from 3.0% to 1.6% (HR 0.55, 95% 
0.31 to 0.96; p=0.034). Although a similar effect size was 
seen in those allocated to CTCA in the non-anginal cohort, the 
CI was wide, reflecting the lower event rate, and this did not 
achieve statistical significance (HR 0.65; 95% CI 0.25 to 1.69; 
p=0.379, figure 3b). The treatment-group interaction p value 
was 0.836.
The use of CTCA was not associated with an increase in coro-
nary revascularisation in either the possible angina (18.7% vs 
16.5%; HR 1.16, 95% CI 0.95 to 1.41, p=0.140) or non-an-
ginal cohorts (2.2% vs 1.9%; HR 1.20, 95% CI 0.59 to 2.46, 
p=0.619).
dIsCussIOn
We have applied the updated 2016 NICE guideline criteria to 
a prior large multicentre randomised controlled trial popula-
tion. We have demonstrated that the selective investigation of 
patients with possible angina produced the greatest absolute 
benefits in terms of diagnostic certainty, use of invasive angiog-
raphy, targeting of therapies and ultimately improving clinical 
outcome. In contrast, CTCA was not associated with a signif-
icant improvement in outcomes in patients with non-anginal 
symptoms and a normal resting ECG despite nearly doubling 
rates of invasive coronary angiography. These findings provide 
Table 2 Findings of CTCA
non-anginal Possible angina
n 592 1027
Coronary calcium score
  Low (<100 AU), 478 (80.7) 646 (63.0)
  Medium (100–400 AU) 68 (11.5) 197 (19.2)
  High (>400 AU) 46 (7.8) 183 (17.8)
CTCA findings
  Normal 295 (50.0) 339 (33.3)
  Mild (<50%) 158 (26.8) 195 (19.1)
  Moderate (50%–70%) 81 (13.7) 182 (17.9)
  Obstructive 56 (9.5) 303 (29.7)
Prognostic CHD 8 (1.4) 86 (8.4)
CHD, coronary heart disease; CTCA, CT coronary angiography.
Figure 2 Diagnostic certainty, pharmacotherapeutic changes and effect on invasive angiography with standard care (blue) or standard care plus 
CTCA (red) according to diagnostic cohort. CHD, coronary heart disease; CTCA, CT coronary angiography.
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robust evidence to support the diagnostic strategy recommended 
within the new NICE guidelines.
This study has five notable strengths. First, the study partic-
ipants were recruited from an unselected patient population 
referred to 12 chest pain clinics across Scotland and thereby 
accurately reflect the target cohort of the new guidelines. Second, 
as participants were allocated to CTCA in a randomised manner 
regardless of the typicality of chest pain symptoms, we mini-
mised the potential for case ascertainment bias. Third, by not 
dictating the use of additional investigations in the standard care 
arm, we have focused on the effect of CTCA on clinically signif-
icant outcomes rather than comparing the diagnostic accuracy of 
Table 3 Clinical endpoints according to diagnostic cohort
(A) Possible angina*
standard care standard care and CTCA hr (95% CI) p Value
Fatal and non-fatal MI 37 (3.2) 22 (1.9) 0.58 (0.34 to 0.99) 0.045
Fatal MI, non-fatal MI and stroke 40 (3.5) 28 (2.4) 0.69 (0.42 to 1.11) 0.128
Non-fatal MI 34 (3.0) 19 (1.6) 0.54 (0.31 to 0.96) 0.034
Non-fatal stroke 6 (0.5) 6 (0.5) 1.01 (0.32 to 3.12) 0.991
All-cause death 22 (1.9) 18 (1.5) 0.82 (0.44 to 1.53) 0.536
CHD death 4 (0.3) 3 (0.3) 0.78 (0.17 to 3.48) 0.742
Non-CHD death 18 (1.6) 15 (1.3) 0.83 (0.42 to 1.65) 0.598
Coronary revascularisation 190 (16.5) 220 (18.7) 1.16 (0.95 to 1.41) 0.140
PCI 151 (13.1) 170 (14.5) 1.11 (0.89 to 1.38) 0.349
CABG 43 (3.7) 56 (4.8) 1.3 (0.87 to 1.94) 0.198
(b) non-anginal*
standard care standard care and CTCA hr (95% CI) p Value pinteraction
Fatal and non-fatal MI 11 (1.5) 7 (1.0) 0.65 (0.25 to 1.69) 0.379 0.836
Fatal MI, non-fatal MI and stroke 16 (2.2) 8 (1.1) 0.51 (0.22 to 1.2) 0.123 0.554
  Non-fatal MI 9 (1.2) 7 (1.0) 0.8 (0.3 to 2.14) 0.654 0.509
  Non-fatal stroke 5 (0.7) 1 (0.1) 0.21 (0.02 to 1.8) 0.155 0.200
All-cause death 4 (0.5) 7 (1.0) 1.81 (0.53 to 6.18) 0.346 0.269
  CHD death 2 (0.3) 0 (0.0) 0 (0 - Inf) 0.999 0.998
  Non-CHD death 2 (0.3) 7 (1.0) 3.64 (0.75 to 17.57) 0.108 0.096
Coronary revascularisation 14 (1.0) 16 (2.2) 1.2 (0.59 to 2.46) 0.619 0.938
  PCI 13 (1.8) 14 (2.0) 1.13 (0.53 to 2.40) 0.753 0.978
  CABG 1 (0.1) 2 (0.3) 1.85 (0.16 to 20.92) 0.620 0.704
CABG, coronary artery bypass grafting; CHD, coronary heart disease; MI, myocardial infarction; PCI, percutaneous coronary intervention.
Figure 3 Cumulative event curves for fatal and non-fatal myocardial infarction in the possible angina (solid lines) and non-anginal (dashed lines) 
cohorts in patients assigned to standard care (blue) and standard care plus CTCA (red). CTCA, CT coronary angiography.
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different imaging modalities. Fourth, all scans were performed 
on CT scanners meeting or exceeding the guideline technolog-
ical requirements and were reported in accordance with the 
recommended definitions for obstructive CHD. Finally, the 
prospective nature of the SCOT-HEART trial enabled detailed 
and accurate phenotypic characterisation of patients at baseline 
and comprehensive clinical follow-up.
The use of CTCA in the assessment of patients with possible 
angina results in a 1.3% absolute risk reduction in the prog-
nostic endpoint of fatal or non-fatal myocardial infarction 
over 3.2 years. This corresponds to 74 CTCA referrals (65 
completed scans) to prevent a myocardial infarct. It should 
be noted that both cohorts had numerically similar HRs and 
failed to demonstrate a statistically different treatment effect 
on formal interaction testing. Consequently, the non-signif-
icant risk reduction in the non-anginal cohort likely relates 
to the very low event rate observed within this group. While 
this study was underpowered to reliably exclude a benefit in 
the non-anginal cohort, the results do suggest that the clinical 
significance of any benefits are likely to be small with an esti-
mated number of 195 CTCA referrals to prevent a myocardial 
infarct.
An important innovation of the 2010 NICE guidelines was 
the recommendation to avoid further testing in patients with 
a low likelihood (<10%) of CHD. This has a sound theoret-
ical basis in probability theory, reduces unnecessary investiga-
tions and is similar to the approach adopted by the European 
Society of Cardiology.21 Despite this, the explicit calculation 
of risk has been removed from the updated recommendations 
due to the questionable applicability of the established scoring 
system—developed in 1979 within a US population—to the 
modern UK context, resulting in potential overestimation of 
disease prevalence. Fortuitously, in this study, the cohort with 
non-anginal symptoms and a normal ECG had a prevalence 
of obstructive CHD of 9.5%, suggesting that the updated 
approach continues to provide an implicit method of pretest 
probability estimation. It is important to note, however, 
that within the non-anginal group, there is some underlying 
heterogeneity in risk by age and sex—the predicted risk of 
obstructive CHD does vary from 3.4% in women aged less 
than 60 years of age to 20.2% in men aged over 60 years—and 
it is likely that including routinely recorded clinical variables 
such as these could further optimise the assessment process.22 
Nonetheless, our study suggests that deferring the use of addi-
tional cardiac testing in these patients is safe, with an inci-
dence of fatal or non-fatal myocardial infarction during the 
follow-up period of 1.5%, which was not reduced with the 
use of CTCA.
Within this study, CTCA increased the identification of both 
obstructive and non-obstructive coronary atherosclerosis that 
led to an increase in new requests for invasive coronary angi-
ography in both patient cohorts. This increase in referrals has 
been raised as a potential drawback of adopting an anatomical 
approach to coronary assessment given the associated costs of 
unnecessary downstream testing.12 Such concern is justified 
if CTCA is applied in an indiscriminate manner. Indeed, this 
study found no decrease in the likelihood of finding normal 
coronary arteries in those patients with non-anginal symp-
toms who underwent invasive evaluation, implying that CTCA 
did not improve appropriate test selection in this group. In 
contrast, when restricted to use in patients with possible 
angina, there was a reduction in the likelihood of normal 
coronary arteries and an increase in the rate of obstructive 
disease found on angiography suggesting that candidates for 
further testing had been appropriately selected. Furthermore, 
although both groups demonstrated higher rates of invasive 
angiography at 6 weeks, this increase only persisted in the 
non-anginal cohort by the conclusion of study follow-up. 
Interestingly, despite the increased detection of coronary 
obstruction on angiography, there was no increase in coro-
nary revascularisation in patients with possible angina. This 
suggests the adoption of a more nuanced approach to coro-
nary intervention in the modern era. Our findings therefore 
refute previous commentators’ criticisms of the 2016 NICE 
guidance and their assumptions regarding CTCA-guided use 
of both angiography and revascularisation.12
limitations
Although this was a post hoc analysis of the SCOT-HEART 
trial, it took place during the prespecified period of follow-up 
of clinical events with systematic and robust collection of 
outcome data. Furthermore, the original trial was pragmati-
cally designed in order to recruit patients with suspected stable 
angina of recent onset in a non-selective manner, and the popu-
lation enrolled is reflective of the heterogenous group seen in 
chest pain clinics with an even spread of chest pain symptom 
typicality. In addition, participants had a broad range of esti-
mated pretest probability of CHD, thereby ensuring direct 
applicability of the study outcomes to the proposed setting for 
implementation of the updated NICE guidelines.
It should be noted that, within this study, clinicians made 
use of additional ischaemia tests, particularly exercise ECG, 
that are no longer recommended by current guidelines. This 
does not necessarily detract from the overall findings. Indeed, 
it could be claimed that the high use of exercise ECG in both 
treatment arms would likely reduce the incremental benefit 
of CTCA compared with the recommended avoidance of this 
investigation.
Finally, it is uncommon for trials of diagnostic investigations 
to demonstrate improvements in clinical outcomes, and this 
study cannot answer the question of how this reduction in event 
rates was achieved. It seems plausible that the identification of 
CHD initiated a series of management changes including more 
personalised patient education, greater adherence to healthy 
lifestyle recommendations and more appropriate use of 
risk-modifying medications.23 Uncertainty persists concerning 
how to manage patients with no evidence of atherosclerosis 
on CTCA, specifically whether this warrants the cessation of 
preventative medications even in the presence of other cardio-
vascular risk factors. Furthermore, we have previously demon-
strated a gradient of risk between the categories of normal, 
non-obstructive and obstructive coronary artery disease23 and 
the ability to robustly quantify plaque burden is an important 
strength of CTCA. How this information is best used to 
inform treatment decisions, however, remains an important 
unanswered question, particularly in light of recent effective 
but costly pharmacological interventions.24
COnClusIOns
The clinical characterisation of symptoms is central to the 2016 
updated NICE guidelines for the assessment of chest pain. When 
applied to a modern chest pain cohort, this revised approach 
appropriately selects patients requiring further investigation for 
CHD and minimises unnecessary testing in low-risk individ-
uals. Once patients with possible angina are identified, the use 
of CTCA is associated with greater diagnostic certainty, more 
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appropriate use of invasive angiography and a reduced risk of 
fatal and non-fatal myocardial infarction.
Key questions
What is already known on this subject?
 ► CT coronary angiography (CTCA) enhances the assessment 
of patients with suspected stable angina by increasing 
diagnostic certainty when applied to a broad population 
referred to a specialist chest pain clinic. The recently updated 
2016 National Institute for Health and Care Excellence (NICE) 
guidelines advocate use of CTCA for a subset of this 
population only.
What might this study add?
 ► The present study investigated the diagnostic and prognostic 
impact of CTCA when used in accordance with the new 
NICE guidance. Selective use of CTCA in patients with 
possible angina maximises the benefits of CTCA including 
greater diagnostic certainty, avoidance of normal invasive 
coronary angiography and reductions in fatal and non-fatal 
myocardial infarction. It also demonstrates that patients 
with non-anginal symptoms are at low risk and do not derive 
major diagnostic or prognostic benefit from CTCA, but its use 
is associated with greater rates of invasive angiography.
how might this impact on clinical practice?
 ► These findings offer clinicians robust evidence of the safety 
and efficacy of the revised NICE guidelines and provide 
healthcare services some reassurance that such an approach 
does not increase downstream use of invasive coronary 
angiography. In keeping with these updated NICE guidelines, 
CTCA should only be used where there is diagnostic 
uncertainty in patients with possible angina.
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